Skip to main content

Table 1 Different trials

From: An effective stability indicating RP-HPLC method for simultaneous estimation of Dolutegravir and Lamivudine in bulk and their tablet dosage form

TrailColumnBufferMobile phaseFlow rate ml/minObservation
1ODS (150 × 4.6 mm, 5 μm)0.1% TFA in waterBuffer: methanol (40:60)1Peaks were not good
2Xterra RPC18 (150 × 4.6 mm, 5 μm)0.1% formic acid in waterBuffer: ACN (50:50)1Broad peak for Dolutegravir
3Xterra RPC18 (150 × 4.6 mm, 5 μm)0.1% formic acid in waterBuffer: ACN (20:80)1Peak of Dolutegravir was not good
4Phenyl XDB (250 × 4.6 mm, 5 μm)0.1% TFA in waterBuffer: ACN (40:60)1Resolution of peaks was not good, and peak of Dolutegravir was not good
5Phenyl XDB (250 × 4.6 mm, 5 μm)0.1% TFA in waterBuffer: methanol (50:50)0.8No peak is observed for Dolutegravir
6Phenyl XDB (250 × 4.6 mm, 5 μm)0.1% TFA in waterBuffer: methanol (20:80)0.8Long RT of Dolutegravir
7Phenyl XDB (250 × 4.6 mm, 5 μm)0.1% TFA in waterBuffer: methanol (15:85)0.8Good resolution and good shape of peaks
  1. ODS octadecylsilane, TFA trifluoroacetic acid, XBD extra dense bonding, ACN acetonitrile